

Reviewer #1:

**Scientific Quality:** Grade B (Very good)

**Language Quality:** Grade B (Minor language polishing)

**Conclusion:** Accept (General priority)

**Specific Comments to Authors:**

1. Overall Evaluation: Overall, the article is exceptionally detailed and insightful, offering an extensive exploration of the present state of research and the forthcoming advancements in colorectal cancer immunotherapy. The explanations of the findings are lucid and provide profound insights into their scientific significance and relevance within clinical practice. The article maintains a well-structured logical flow and effectively conveys its message in a relatively concise and clear manner. Nevertheless, a few minor revisions are suggested to further enhance the article's quality.

Response: Dear reviewer, thank you for your thoughtful and comprehensive review of our article on colorectal cancer immunotherapy. We appreciate the details to highlight both the potential and limitations of our manuscript in context to immunotherapy in colorectal cancer. Your input is invaluable to us, and we have taken it into careful consideration as we strive to improve and refine our work.

2. Specific Suggestions: Abstract: The abstract summarizes and reflects the work described in the manuscript. It provides information on colorectal cancer (CRC) treatment challenges, the role and limitations of immune checkpoint inhibitors, the importance of pivotal clinical trials, and primary and secondary drug resistance. The abstract highlights the potential and limitations of immunotherapy in the field of CRC and mentions future research directions.

Response: Dear reviewer, thank you for your detailed insights on the abstract of our article. We're grateful for your support and for taking the time to share your insights with us.

3. Background: The manuscript adequately describes the background, current status, and significance of the research. Overall, the article provides in-depth background information that highlights current challenges in the field of CRC treatment and the promise of immunotherapy, as well as the importance of future research. Challenges in the field of CRC treatment, especially in advanced or metastatic disease, and potential opportunities for immunotherapy can be appropriately emphasized. This helps to highlight the importance of immunotherapy. In terms of the section elucidating the mechanism of action of immune checkpoint inhibitors in

colorectal cancer, if there are relevant recent research advances or clinical trial results, they can be considered to be added to the text to provide more comprehensive information.

Response: Dear reviewer, thank you for your feedback. We appreciate your acknowledgment of the thorough background information provided. We have taken your suggestions into consideration and have now highlighted both the challenges in CRC treatment focusing on advanced and metastatic disease, and the potential of immunotherapy in this area. Your suggestion regarding recent research advances or clinical trial results related to the mechanism of action of immune checkpoint inhibitors have also been considered to enhance the comprehensiveness of our work. We're grateful for your valuable feedback.

4. Conclusion and Discussion: The conclusion and discussion should sum up the current status of immunotherapy in the treatment of colorectal cancer. It should emphasize the accomplishments attained and underscore the challenges that remain to be addressed. Incorporating more up-to-date citations and literature support would strengthen the overall arguments and points.

Response: Dear reviewer, thank you for your insightful feedback regarding the conclusion and discussion section of our manuscript. We have now included a new sub-section in our article discussing the current status of immunotherapy in colorectal cancer treatment and have incorporated more up-to-date citations and literature support to strengthen the accomplishments and challenges in CRC immunotherapy, ensuring that the conclusion and discussion provide a comprehensive overview of the topic.

5. The future directions section can be more comprehensively detailed, encompassing discussions on combination therapies, biomarker research, early colorectal cancer treatment, strategies for overcoming drug resistance, and the implementation of personalized medicine. A brief exploration of the potential implications of these future developments in clinical practice would be beneficial in helping readers understand their potential impact on patient care and survival. These revisions and enhancements will further augment the overall quality and impact of the article.

Response: Dear reviewer, thank you for feedback. Your input is crucial in ensuring that our manuscript thoroughly covers essential areas of interest and delivers valuable insights to our readers. Based on your suggestion, we have now elaborated this section to cover more comprehensively overview of the potential implications of these future developments in clinical practice.

## EDITORIAL OFFICE'S COMMENTS

Authors must revise the manuscript according to the Editorial Office's comments and suggestions, which are listed below:

### **(1) Science editor:**

**1 Conflict of interest statement:** Academic Editor has no conflict of interest.

**2 Scientific quality:** The author submitted a study of molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer. The manuscript is overall qualified.

**(1) Advantages and disadvantages:** The reviewer have given positive peer-review reports for the manuscript. Classification: Grade B; Language Quality: Grade B. The article is exceptionally detailed and insightful, offering an extensive exploration of the present state of research and the forthcoming advancements in colorectal cancer immunotherapy. The manuscript adequately describes the background, current status, and significance of the research. A brief exploration of the potential implications of these future developments in clinical practice would be beneficial in helping readers understand their potential impact on patient care and survival. These revisions and enhancements will further augment the overall quality and impact of the article.

**(2) Main manuscript content:** The author clearly stated the purpose of the study and the research structure is complete. However, the manuscript is still required a further revision according to the detailed comments listed below.

**(3) Table(s) and figure(s):** There are 2 Figures and 1 Table should be improved. Detailed suggestions for each are listed in the specific comments section.

**(4) References:** A total of 196 references are cited, including 29 published in the last 3 years. The reviewer didn't request the authors to cite improper references published by him/herself.

**3 Language evaluation:** The English-language grammatical presentation needs to be improved to a certain extent. There are many errors in grammar and format, throughout the entire manuscript. Before final acceptance, the authors must provide the English Language Certificate issued by a professional English language editing company. Please visit the following website for the professional English language editing companies we recommend: <https://www.wjgnet.com/bpg/gerinfo/240>.

**4 Specific comments:** (1) Please provide the filled conflict-of-interest disclosure form.

(2) Please provide the Figures cited in the original manuscript in the form of PPT. All text can be edited, including A, B, arrows, etc. All legends are incorrectly formatted and require a general title and explanation for each figure. Such as Figure 1 title. A: ; B: ; C: .

(3) Please obtain permission for the use of picture(s). If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published, and correctly indicate the reference source and copyrights. For

example, “**Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×)**. A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. **Citation:** Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. *World J Gastroenterol* 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc<sup>[6]</sup>”. And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable.

**5 Recommendation:** Conditional acceptance.

Language            Quality:            Grade            B            (Minor            language            polishing)  
Scientific Quality: Grade B (Very good)

**(2) Company editor-in-chief:**

I have reviewed the Peer-Review Report, full text of the manuscript, all of which have met the basic publishing requirements of the **World Journal of Gastroenterology**, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office’s comments and the Criteria for Manuscript Revision by Authors.

Response:

Dear Esteemed Editors,

We extend our sincerest appreciation for the invaluable feedback and insightful comments you have provided to enhance the quality of our work. Your guidance has been instrumental in refining our manuscript, and we are grateful for your expertise and dedication to scholarly excellence.

In response to your recommendations, we have diligently revised our manuscript, ensuring that all suggested enhancements have been carefully incorporated. Additionally, the tables and figures have been revised in accordance with the provided suggestions. Furthermore, we have availed Wiley's English editing service to further refine the language and clarity of our manuscript, as evidenced by the accompanying certificate.

We wish to express our utmost gratitude for your continued support and guidance throughout this process.

With sincere thanks and warm regards,

Samantha Sharma  
Assistant Research Scientist  
Indiana University School of Medicine  
Medical & Molecular Genetics

R3 Building  
980 W. Walnut Street, Room C260  
Indianapolis, IN 46202  
P: 317-278-8194  
Email: [samshar@iu.edu](mailto:samshar@iu.edu)